StockData
Lisata Therapeutics, Inc. logo

Lisata Therapeutics, Inc. (LSTA) stock

LSTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.91−0.07 (-7.15%)

Close on Nov 19, 2026Market cap $8.20MP/E –Yield –

Lisata Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Lisata Therapeutics's gross profit for the twelve months ending Mar 31, 2017 was $2.77M. For fiscal 2016 it was $4.15M, up 78.1% from the year before. The highest annual figure on record is $20.15M in fiscal 2010.

Annual gross profit

PeriodPeriod endValueChange
FY2016Dec 31, 2016$4.15M+78.1%
FY2015Dec 31, 2015$2.33M+3.0%
FY2014Dec 31, 2014$2.26M+31.3%
FY2013Dec 31, 2013$1.72M-27.7%
FY2012Dec 31, 2012$2.38M+69.6%
FY2011Dec 31, 2011$1.40M-93.0%
FY2010Dec 31, 2010$20.15M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2017Mar 31, 2017-$119.60K–
Q4 FY2016Dec 31, 2016$931.36K–
Q3 FY2016Sep 30, 2016$706.27K–

More Lisata Therapeutics figures

See a number that looks wrong?